Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a talking jigsaw puzzle lift mood in early dementia?

NCT ID NCT07839286

Symptom relief Sponsor: Callahan-Young LLC DBA Jigsawdio Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 24, 2026 · Last updated Sep 25, 2026 · Updated 1 time

Summary

Researchers are testing Jigsawdio, a puzzle platform that combines clear physical pieces with personal photos, stories, and sound played through an iPad. The study enrolls about 80 adults aged 60 and older with mild cognitive impairment or mild dementia. Half use Jigsawdio and half use standard dementia-friendly puzzles, both for two 30- to 40-minute sessions a week over six weeks. The team measures changes in quality of life, depression, anxiety, and thinking skills.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Jigsawdio, a personalized multisensory jigsaw puzzle platform that pairs physical puzzle pieces with images, stories, and audio on an iPad
What this could lead to
If it helps, this could offer a low-cost, engaging activity that supports mood and quality of life for people with mild memory problems.
What could go wrong
This is a small, six-week study of a single activity, so any benefits may be modest or fade. Puzzles are not a treatment for dementia, and results may not apply to people with more advanced disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age: 60 years or older. 2. Able to communicate fluently in English. 3. Mild cognitive impairment or mild dementia based on an existing diagnosis or study screening procedures. 4. Has an informant and a puzzle creator who know the participant and are willing to participate in the study; the same person may serve in both roles. Exclusion Criteria: 1. Severe uncorrected visual or hearing impairment that would prevent puzzle use. 2. Severe motor impairment that would prevent puzzle use. 3. Concurrent participation in a similar program or Alzheimer's disease intervention study. 4. Current hospice care or terminal illness. 5. Plans to relocate within three months after the baseline assessment. 6. History of a serious mental illness, such as bipolar disorder or schizophrenia, that would interfere with study participation. 7. Unable to provide informed consent and no legally authorized representative is available

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Dementia Mild cognitive impairment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Duke University

    Durham, North Carolina, 27710, United States

  • Texas A&M University

    College Station, Texas, 77843, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.